Thomas Burke, HMS assistant professor of surgery at Massachusetts General Hospital, was preparing to begin a 10-year cooperative effort between Mass. General and Benghazi Medical Center to develop an emergency care infrastructure when tragedy struck. Just hours before Burke was scheduled to meet with John Christopher Stevens, the US ambassador to Libya, the US consulate was attacked.
Lewis Cantley, the William Bosworth Castle Professor of Medicine at Beth Israel Deaconess Medical Center, is leaving Harvard to head the new cancer center at New York City’s Weill Cornell Medical College and New York-Presbyterian Hospital. His appointment is effective Oct. 15.
Social isolation in youth may wreak havoc on the brain by disrupting a protein crucial to the development of the nervous system’s support cells, new research finds. Gabriel Corfas, HMS professor of neurology at Boston Children’s Hospital, led the study.
A centerpiece of Beth Israel Deaconess Medical Center’s IT-based innovation is a new medical informatics platform called Clinical Query, a search engine married to a huge database of patient records that lets hospital employees test hypotheses about what causes a disease, for instance, or test which drug, diet, or lifestyle variables may reduce the risk of developing one. John Halamka, CIO of Beth Israel Deaconess Medical Center and HMS professor of medicine, is quoted.
Brigham and Women’s Hospital surgeons said at a news conference yesterday that the hospital has approved a patient for transplant surgery — the first double arm transplant above the elbow to be performed in the United States. Bohdan Pomahac, HMS associate professor of surgery at Brigham and Women’s Hospital, is quoted.
New research shows that talking to your doctor about a medication’s possible side effects — just hearing about the high blood pressure or abnormal vision — may increase the chance that you actually experience them. Ted Kaptchuk, HMS associate professor of medicine at Beth Israel Deaconess Medical Center and Arthur Barsky, HMS professor of psychiatry at Brigham and Women’s Hospital, spoke about this topic on Radio Boston.
Johnson & Johnson and Pfizer Inc.’s bapineuzumab, an experimental drug that failed to help Alzheimer’s symptoms in a study, showed signs of reducing physical damage in the brain, according to a deeper analysis. Reisa Sperling, HMS professor of neurology at Brigham and Women’s Hospital, led one of the studies.
